HC Wainwright Issues Negative Forecast for Invivyd Earnings

Invivyd, Inc. (NASDAQ:IVVD) – Equities researchers at HC Wainwright reduced their Q2 2026 earnings estimates for Invivyd in a research report issued on Tuesday, May 19th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.15) per share for the quarter, down from their previous estimate of ($0.09). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Invivyd’s Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.48) EPS and FY2027 earnings at ($0.28) EPS.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.05). Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%.The company had revenue of $13.74 million for the quarter, compared to analyst estimates of $18.04 million.

IVVD has been the subject of several other research reports. BTIG Research reaffirmed a “buy” rating and set a $10.00 price target on shares of Invivyd in a research report on Monday. Wall Street Zen lowered shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research report on Wednesday, April 29th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $8.00.

Invivyd Stock Performance

Shares of IVVD stock opened at $1.09 on Thursday. Invivyd has a one year low of $0.48 and a one year high of $3.07. The company has a 50 day moving average price of $1.48 and a 200 day moving average price of $1.88. The firm has a market capitalization of $321.12 million, a price-to-earnings ratio of -3.52 and a beta of 0.71.

Institutional Investors Weigh In On Invivyd

Several large investors have recently made changes to their positions in IVVD. Perceptive Advisors LLC acquired a new stake in shares of Invivyd in the fourth quarter worth $53,809,000. BVF Inc. IL acquired a new stake in shares of Invivyd in the fourth quarter worth $48,227,000. RA Capital Management L.P. acquired a new stake in shares of Invivyd in the third quarter worth $18,831,000. ADAR1 Capital Management LLC acquired a new stake in shares of Invivyd in the third quarter worth $8,108,000. Finally, Janus Henderson Group PLC increased its position in shares of Invivyd by 28.2% in the fourth quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock worth $80,870,000 after acquiring an additional 7,160,065 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.